FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

QVT Associates GP LLC

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/27/2010 

3. Issuer Name and Ticker or Trading Symbol

Molecular Insight Pharmaceuticals, Inc. [MIPI]

(Last)        (First)        (Middle)

1177 AVENUE OF THE AMERICAS, 9TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
_____ Officer (give title below)          ___ X ___ Other (specify below)
/ reference remarks (2) below

(Street)

NEW YORK, NY 10036       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

6/30/2010 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.01 per share   364581   (1) I   Through QVT Fund LP and Quintessence Fund L.P.  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant for Common Stock   11/16/2007   11/16/2012   Common Stock, par value $0.01 per share   1685949   (1) $5.87   I   Through QVT Fund LP and Quintessence Fund L.P.  

Explanation of Responses:
( 1)  QVT Fund LP directly beneficially owns 328,063 shares of Common Stock and 1,520,661 Warrants. Quintessence Fund L.P. directly beneficially owns 36,518 shares of Common Stock and 165,288 Warrants. QVT Associates GP LLC, as General Partner of QVT Fund LP and Quintessence Fund L.P., may be deemed to beneficially own the aggregate number of shares of Common Stock owned by QVT Fund LP and Quintessence Fund L.P. and accordingly, QVT Associates GP LLC may be deemed to be the indirect beneficial owner of an aggregate amount of 364,581 shares of Common Stock and 1,685,949 Warrants. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

Remarks:
(2) As of June 27, 2010, each of the reporting persons may be deemed to be a member of a "group" with certain other holders of equity securities and/or derivative securities of the Issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. If such a group were determined to exist, the members hold in the aggregate more than ten percent (10%) of the Issuer's equity securities. However, each reporting person disclaims the existence of such a group and disclaims beneficial ownership of any equity securities and/or derivative securities of the Issuer other than those set forth above. This report shall not be deemed an admission that any reporting person is a member of a Section 13(d) group, for purposes of Section 16 or for any other purpose.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
QVT Associates GP LLC
1177 AVENUE OF THE AMERICAS
9TH FLOOR
NEW YORK, NY 10036


reference remarks (2) below
QVT Fund LP
WALKERS SPV, WALKERS HOUSE
87 MARY STREET
GEORGE TOWN, GRAND CAYMAN, E9 KY1-9005


reference remarks (2) below
Quintessence Fund L.P.
WALKERS SPV, WALKER HOUSE
87 MARY STREET
GEORGE TOWN, GRAND CAYMAN, E9 KY1-9005


reference remarks (2) below

Signatures
/s/ Tracy Fu, Managing Member 6/29/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).